Wednesday Mar 5
Facility Concerns Kill Lilly-Boehringer Diabetes Drug
Eli Lilly and Boehringer-Ingelheim said that the Food and Drug Administration didn't approve their diabetes treatment empagliflozin because of concerns about a facility where the drug will be made.
San Bernardino County Sun
Drug companies cutting back on marketing fees to doctors
The Eli Lilly and Co. corporate headquarters in Indianapolis. Eli Lilly & Co. is spending less on promotional speakers for its drugs now that Cymbalta and others have gone generic.
Lilly diabetes drug meets late-stage goal
Eli Lilly and Co.' s experimental injectable diabetes treatment dulaglutide fared on par in a late-stage study with another drug that's already on the market.
Five Star Equities Issues New Research Reports on DVN, LLY, SIG and...
The stock traded between $63.31 and $65.64 on volume of 9.1 million shares traded.
The Miami Herald
Lilly 4Q profit falls 12 pct, hurt by patent loss
Eli Lilly and Co.' s fourth-quarter earnings dropped 12 percent as the drugmaker lost U.S. patent protection for its top-selling product, and cheaper generic competition started to eat away at results.